Related Experiment Video
Updated: Aug 22, 2025

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
A Case Series of Myocarditis Related to the COVID-19 Vaccine
Hayfa O Ahmed1, Mawada M Ahmed1, Omer Elrasheid1
1Cardiology, Security Forces Hospital, Riyadh, SAU.
Insights
Rare cases of perimyocarditis linked to the COVID-19 vaccine have been observed. Most patients with vaccine-related myocarditis/pericarditis recover fully, but some may experience persistent heart dysfunction.
Area of Science:
- Cardiology
- Vaccinology
- Infectious Diseases
Background:
- Messenger RNA (mRNA) COVID-19 vaccines have been associated with rare cases of perimyocarditis.
- The incidence of these adverse events increased with the rise in vaccination rates.
Observation:
- This case series details four distinct presentations of myocarditis/pericarditis following mRNA COVID-19 vaccination.
- Patient outcomes varied, highlighting the spectrum of this rare vaccine side effect.
Findings:
- Three out of four patients achieved full recovery within 1 to 12 weeks.
- One patient exhibited persistent left ventricular systolic dysfunction, necessitating ongoing monitoring.
Implications:
- While generally rare, vaccine-associated myocarditis/pericarditis requires careful monitoring and further investigation into long-term outcomes.
- Understanding the varied presentations and recovery trajectories is crucial for clinical management and patient counseling.
Abstract:
Perimyocarditis related to the coronavirus disease 2019 (COVID-19) vaccine is one of the rare adverse events that emerged in April 2021 and then the number of cases commensurably increased as the number of vaccinated people rose. This is a case series of myocarditis/pericarditis related to the messenger RNA (mRNA) COVID-19 vaccine in which we identified four cases with different presentations and outcomes. A short-term follow-up period of five months revealed a full recovery of three cases within one to 12 weeks and persistent left ventricular systolic dysfunction in the fourth case which will require further follow-up to assess long-term outcomes.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis IV: Nursing Management
Pericarditis I: Introduction
Pericarditis III: Medical Management

